Skip to content

Effectiveness and Safety of Rhubarb for the Treatment of Patients Who Have Suffered From a Stroke

Status
UNKNOWN
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00789269
Enrollment
100
Registered
2008-11-11
Start date
2009-01-31
Completion date
Unknown
Last updated
2010-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pneumonia, Acute Stroke

Keywords

lung infection after ischemic Stroke, prevention of pneumonia, rhubarb

Brief summary

This study will determine if rhubarb will reduced the incidence of pneumonia and improved recovery from an acute stroke. The study is designed to look at both infection rate and overall recovery and recovery of motor function, for example muscle strength and coordination.

Interventions

14 days of rhubarb

DRUGplacebo

14 days of placebo

Sponsors

Fudan University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Occurrence of an acute ischemic stroke (between 9 and 72 h after onset) with a score of at least 6 on the National Institute of Health Stroke Scale (NIHSS), and patient age of at least 18 years. * Have no pneumonia according to modified criteria of the U.S. Centers for Disease Control and Prevention (CDC) * Consistent with the Constipation of Phlegm-Heat Accumulation type by Traditional Chinese Medicine (TCM) standard * Patients or their representatives voluntarily take part in this study and signed the informed consent

Exclusion criteria

* Cerebral hemorrhage, subarachnoid hemorrhage * Transient ischemic attack(TIA) * Proven cerebral embolism caused by tumor, Brain Trauma, cerebral parasitic disease, dysbolismus, fibrillation atrial resulted from rheumatic heart disease, coronary heart disease, and other heart diseases * Clinical signs of infection on admission * Pregnant or breast-feeding * Allergic to rhubarb * Preceding or ongoing antibiotic therapy within the last 24 h * Participation in another interventional trial * Immunosuppressant treatment within the last 30 days * Combining severe clinical conditions such as liver, kidney, Hematopoietic System, endocrine system or psychological diseases

Design outcomes

Primary

MeasureTime frame
The lung infection rate within 14 days after stroke onset14 days

Secondary

MeasureTime frame
NIH stroke scale90 days
Barthel Index90 days
Global disability on modified Rankin scale90 days
Syndrome score by Traditional Chinese Medicine (TCM) standard90 days
Changes in laboratory indexes as safety assessment, including red blood cell(RBC), white blood cell(WBC), platelet(PLT), alanine transaminase (ALT), aspartate transaminase (AST), blood urea nitrogen (BUN), creatinine(Cr) in blood samples, etc.90 days
Death rate90 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026